BeiGene Terminates its Worldwide Development and Commercialization Agreement with Celgene for Tislelizumab

BeiGene Terminates its Worldwide Development and Commercialization Agreement with Celgene for Tislelizumab

Shots:

  • BeiGene to receive $150M and regains WW rights for tislelizumab with their mutual termination of WW development & commercialization agreement with Celgene, following the pending acquisition of Celgene by BMS
  • In Jul’17, BeiGene granted exclusive WW rights (Ex- Asia) of tislelizumab for solid tumor and retained global rights for hematology & solid tumor in Asia. Additionally, BeiGene got exclusive commercialization rights for Celgene’s Abraxane, Revlimid, Vidaza in China which is unaffected with the termination deal of tislelizumab
  • Tislelizumab (BGB-A317) is an anti-PD-1 antibody, targeting IgG4, minimizing the binding of FcγR on macrophages. NMPA has accepted its NDA for tislelizumab in patients with R/R cHL & LA or metastatic UC and has received PR for R/R cHL filing

Click here to read full press release/ article | Ref: BeiGene | Image: Chemistry World